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Renal osteodystrophy, which influences the quality of life
and contributes to the morbidity of patients with endstage renal
failure [1], has been reported to deteriorate in patients treated
with continuous ambulatory peritoneal dialysis (CAPD) [2].
However, better control of serum calcium and phosphate in
these patients [3] has provided preliminary data that show
improvement in histological grading of osteitis fibrosa (OF) in
our patients treated with CAPD [41.
Another form of bone disease, the osteomalacic dialysis
osteodystrophy (OM), which may be associated with dialysis
encephalopathy, is thought in some instances to be due to
aluminum toxicity [5] from untreated or softened water used in
hemodialysis in areas where the aluminum content of water
supplies is high [6]. In patients undergoing CAPD any exposure
to aluminum is likely to stem from the use of aluminum-
containing phosphate binders (ACPB) since the process of
preparation of peritoneal dialysis fluid reduces most of the trace
metals.
In our unit, since the inception of the CAPD program in
January 1979, 72 patients have been treated by this method in
the first 2 years. In this report we present data on the improve-
ment of histological renal osteodystrophy in CAPD patients and
relate this to serum concentrations of calcium, phosphate, 25
hydroxycholecalciferol [25-(OH)CCJ and immunoreactive para-
thormone (PTH). In addition, sequential serum aluminum con-
centrations are reported. These levels have been related to
concentrations of aluminum in the peritoneal dialysis (PD) fluid
and to the use of ACPB. One patient with aluminum toxicity
prior to starting CAPD was studied to evaluate the chelating
effect of disferrioxamine (DFO) on aluminum and its subse-
quent removal in the PD fluid.
Methods
Over the 2-year period 72 patients (43 male, 29 female; mean
age, 42 years; range, 5 to 66) were treated with CAPD for a
mean period of 7.8 months. Nineteen of these had previously
been managed on hemodialysis (HD) or intermittent peritoneal
dialysis (IPD). Their management, previously described [7],
included the use of PD fluid containing 1.75 mmoles/liter
calcium and 35 mmoles/liter lactate. The daily dietary intake of
calcium was calculated at 600 to 700 mg while that of phosphate
was ito 1.5 g.
Calcium, phosphate, alkaline phosphatase, 25-(OH)CC and
PTH. Forty patients who had been on CAPD for 6 months or
longer were studied. Serial measurements (every 3 to 6 months)
were made of serum ionized and total calcium, phosphate,
alkaline phosphatase, and PTH as previously described [3]. 25-
(OH)CC was measured by a competitive protein binding assay,
involving a preliminary extraction and purification to eliminate
the interference of binding protein 25-(OH)CC that is present in
serum and to remove related substances (mainly vitamin D
itself) that cross react with the 25-(OH)CC binding protein.
Extraction is achieved using chloroform methanol (2:1 v/v), and
purification is performed by column chromatography on selici-
lic acid. Thirty patients of this group received oral calcium
carbonate supplements 1.5 to 3.0 g daily; 11 were treated with 1
hydroxycholecalciferol (1 aOHCC).
Bone histology
Iliac bone biopsies. Transiliac bone biopsy specimens (5 to 7
mm diameters) obtained from 20 patients were examined histo-
logically. Biopsy specimens were embedded in plastic for
preparation of thin (5 m) undecalcified sections, stained with
hematoxylin and eosin, toluidine blue, and by the von Kossa
and Masson-Goldner techniques. Aurine tricarboxylic acid
(Aluminon) [8] was used to demonstrate aluminum at the
mineralization front.
A diagnosis of osteomalacia was made when there was an
excess of osteoid with abnormally wide osteoid seams compris-
ing more than four bright lamellae when viewed between
crossed polaroids and with a reduction in the proportion of
surface osteoid bearing a mineralization front in toluidine blue
stained sections [9]. The amounts of mineralized bone and
osteoid in cancellous bone were determined using the point-
counting technique. Multinucleated osteocaists were counted in
cancellous bone and expressed as the number square millime-
ters of the section. The severity of osteitis fibrosa was graded
on a scale of 0 to 5 depending on the extent of any increased
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Table 1. Bone histology and duration of CAPD in individual patients
resorption, osteoblastic activity, marrow fibrosis, and woven
bone formation [10].
Patients with hone histology. An initial biopsy specimen was
obtained at the commencement of CAPD or within I month in
15 of the 20 patients (listed as 0 in Table 1). In two more patients
the initial biopsy specimen was taken after 2 and 4 months of
CAPD, respectively, and in three at 8, 10, and 16 months prior
to starting CAPD.
At least one additional bone sample was obtained in each of
the 20 patients. One patient died and the second sample was
obtained at necropsy after 4 months of CAPD; in another the
second biopsy was carried out at the time of parathyroidectomy
after 6 months CAPD and in a third at the time of renal
transplantation after 7 months CAPD. In the remaining 17
patients further biopsy specimens were obtained after 10 to 14
months CAPD and in 5 of the 20 a third biopsy was available
after 22 to 24 months CAPD (Tables 1 and 2).
Aluminum levels in serum and PD fluid. The concentration of
serum aluminum was measured at the start of CAPD and then at
three to six monthly intervals in 27 patients; 10 patients were
followed for 19 to 24 months. Nine of these 27 patients had been
exposed previously to aluminum either in the form of ACPB or
as a result of hemodialysis using softened water only. ACPB
were deemed unnecessary for the control of serum phosphate
during CAPD in all but six patients in whom the use of Alucaps
(3 to 6 capsules daily) was begun 9 to IS months after starting
CAPD.
Forty-six normal subjects acted as controls and, in addition,
73 chronic renal failure patients not on dialysis and who had not
been exposed to aluminum also had serum aluminum levels
measured. Aluminum content of PD fluid (Travenol®) was
estimated in ten randomly selected PD bags, together with
effluent samples from the patient study treated with DFO.
Aluminum levels were measured by the flameless atomic
absorption speetrophotometer. Blood samples for these estima-
tions were collected through plastic cannula, and after immedi-
ate separation the serum was stored at —40°C.
Case report
A 52-year-old female, with med ullary cystic fibrosis, reached
endstage renal failure in 1974 and was transplanted. An iliac
crest biopsy specimen showed moderately severe OF (grade
2.5) hut no OM. However, transplant nephrectomy had to be
performed for severe rejection and in 1975 she commenced
hemodialysis, using softened but otherwise untreated water in
an area with a very high aluminum water content. By 1976 the
OF improved by OM had developed, and the bone biopsy
specimen gave a positive staining reaction to aluminum. By
1977 she had very high serum aluminum levels (180 rg/liter)
fracturing osteodystrophy; worse osteomalacia was revealed on
the bone biopsy specimen which again showed a positive stain
for aluminum (dialysis osteodystrophy).
Her treatment was subsequently changed to hemodialysis on
deionized water and over the ensuing 2 years she started
developing soft tissue calcification, probably related to high
phosphate levels and hyperparathyroidism (PTH 2 U/liter,
normal 0 to 1.5; bone biopsy OF grade 2). Subtotal parathyroid-
ectomy (3.5 glands weighing 904 mg) was undertaken in April
1980, by which time she was on CAPD and had developed
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showed severe OF temporarily improved by I OHD1 therapy. Total parathyroideetomy was performed after 6 months of CAPD.
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Table 2. Quantitative bone histological data in CAPD patients
Patient CAPDb
Percent measured area
by
occupied
Percent
.Maximum
number
osteoid Osteomalacia
Number
osteoclasts
Osteitis
fibrosaTotal Mineralized
no. Months bone bone Osteoid mineralization lamellae +7— per mm2 Grade (0 to 5)
2 1" 26.1 24.3 1.80 93.1 3 — 2.59 2.5
3 24 17.0 15.8 1.24 92.7 2 — 0.86 1.5
4 0 19.6 17.0 2.60 86.7 3 — 1.26 2
12 14.1 13.1 0.99 93.0 2 — 0 0
24 23.1 21.9 1.15 95.0 3 — 0.56 0
5 14 17.1 10.9 6.21 63.7 7 + 0.03 0
22c 28.4 20.2 8.15 71.3 7 + 0 0
6 —5 22.9 18.9 4.06 82.3 6 + 0.24 1
Oc 33.6 31.4 2.24 93.3 2 (H) 0.78 1
12 23.5 22.2 1.31 94.4 2 — 0.25 0
24 25.8 24.3 1.47 94.3 2 — 0.17 0
7 4 49.5 45.6 3.83 92.3 3 — 15.62 3.5
10 27.2 25.8 1.43 94.7 2 — 3.73 3
8 0 29.6 27.6 2.06 93.0 1 — 6.34 4
2 34.4 32.1 2.31 93.3 2 — 2.92 3
6 18.4 17.3 1.08 94.1 2 — 2.02 2.5
9a —10 24.3 23.4 0.86 96.4 2 — 0 0
10 0 17.0 16.7 0.27 98.4 2 — 0.30 0
12 18.3 17.8 0.55 97.0 2 — 0 0
11 0 16.7 16.0 0.68 95.9 2 — 0.97 1
14 15.2 13.2 2.00 86.8 2 — 0.03 0
12 —1 20.6 18.7 1.88 90.9 4 — 1.83 2.5
4 14.0 12.6 1.39 90.1 3 — 0.68 1.5
13 9 19.2 18.5 0.73 96.2 3 — 0.18 0
14 0 24.1 21.8 2.26 90.6 2 — 3.10 2.5
l2 21.9 20.2 1.64 92.5 2 — 1.30 1.5
15 0 28.9 26.3 2.57 91.1 3 — 2.48 2
12 21.4 20.0 1.44 93.3 3 — 0.26 1
16 —16 19.5 18.4 1.07 94.5 2 — 0.89 1.5
12 15.4 14.7 0.65 95.8 2 — 0.08 0
17 1 10.8 10.6 0.17 98.4 2 — 0.41 0
18 0 19.5 19.4 0.09 99.5 2 — 0.05 0
19 —8 43.2 28.4 14.79 65.8 8 + 1.94 2.5l2 24.4 23.3 1.15 95.3 2 (H) 0.37 1.5
20 0 36.1 30.6 5.54 84.7 4 — 5.03 3
7c 19.2 18.6 0.56 97.1 2 — 0.39 0
Normal mean SD 22.7
3.1
22.6
3.0
0.13
0.10
99.5
0.4
Ito 4 — 0.08
0.06
—
Patient no. 9 underwent parathyroidectomy 14 months pre-CAPD.
b Less than 1 month from start of CAPD indicated as 0.
"Improvement was evident while the patient took 1 a OHD3.
speech disturbances an impaired memory and intellect, classi-
cal signs of early dialysis dementia.
In view of the report of Ackrill et al relating the successful
use of DFO on an aluminum toxic hemodialysis patient [11],
DFO in 2 g (then 4 g) was given weekly as an intravenous
infusion while CAPD was continued. Serum aluminum levels
and aluminum content of all PD effluents were measured over
the week between injections. After 2 months on this treatment
she reverted to hemodialysis because of peritonitis and DFO
treatment was continued on hemodialysis for a further 2
months.
When giving 2 g DFO i.v. to this patient, the serum aluminum
level rose within 24 hr which coincided with increased alumi-
num in PD fluid (Table 3). This effect of DFO was a maximal 24
to 48 hr after its injection. Overall the use of 4 g DFO once, a
week removed about 4 mg of aluminum which over the 2
months of treatment resulted in the removal of about 30 mg
while a similar quantity would have been lost on hemodialysis.
Over this period, however, there was no change in the neuro-
logical deficit. There were no side effects from the use of DFO.
Results
Calcium, phosphate, and alkaline phosphatase. Serum ion-
ized and total calcium concentrations were within the normal
range while mean serum phosphate levels ranged between 1.5 to
1.8 mmoles/liter without the use of phosphate binders (Fig. 1).
Mean total alkaline phosphatase levels were within the normal
range and individual levels did not correlate with the histologi-
cal grading of OF.
Immunoreactive parathyroid hormone (PTH). PTH levels fell
within the normal range in all but ten patients, six of whom were
previously on hemodialysis with severe OF requiring parathy-
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Table 3. Aluminum levels in serum and PD fluid in relation to use of
desferrioxamine in the aluminum toxic patient
Serum aluminum level at start of
CAPD 69 jig/liter
Serum level 24 h after 2 g DFO iv. 420 jig/liter
Mean aluminum in PH fluid/exchange
in first 24 to 48 hr after
desferrioxamine
Mean aluminum in PH fluid/exchange
after 4 days
Amount aluminum removed in I
week
400 jig
150 jig
4 ing
roidectomy (Fig. 2). Levels in these patients fell subsequently.
25 Hydroxycholecalc(rol /25-(OH)CCJ. These showed a
significant decline to subnormal levels with 12 or more months
of CAPD. Twenty-three patients after 9 months had levels of
less than 10 nmoles/liter (normal range, 10 to 70). In 11 patients
i aOHCC was given as vitamin D replacement therapy. Perito-
neal dialysate effluent showed significant 25-(OH)CC activity
with a mean level of 2.0 nmoles/liter (0 to 4.3; 11 samples) with
protein loss of 0.4 to 1.8 g/liter in the fluid.
Bone histology
Quantitative histology was possible in at least one bone
biopsy specimen from 19 of the 20 patients (Table 2). Some
other biopsy specimens were slightly traumatized and unsuit-
able for quantification.
Initial biopsy. Thirteen patients had some degree of osteitis
fibrosa as revealed in the initial bone biopsy. Four had osteos-
clerosis (total bone >32.3% that is, normal mean 3 SD). Three
of these patients (numbered 7, 19, and 20; Table 2) had severe
osteitis fibrosa, and woven bone contributed to the osteosclero-
sis. In the other patient (no. 6) there was mild osteitis fibrosa
and osteomalacia noted in a biopsy specimen taken 5 months
previously that had largely healed after treatment with I
aOHCC.
Although many patients showed an excess of surface osteoid
of both lamellar and woven texture, this was generally attribut-
able to the osteitis fibrosa; only one patient (no. 19) had
osteomalacia accompanying osteitis fibrosa at the outset of
CAPD.
Subsequent biopsies. (1) Up to 10 months of CAPD. In five
patients a biopsy specimen was obtained after 4 to 10 months of
CAPD. One (no. 13) patient still had no osteitis fibrosa at 9
months, and in two patients severe osteitis fibrosa had im-
proved considerably (no. 8) or resolved (no. 20) after 1 cOHCC
therapy at 6 and 7 months of CAPD, respectively. In the
remaining two patients with initial osteosclerosis this resolved
as the osteitis fibrosa improved (nos. 7 and 20). (2) 12 to 14
months of CAPD. Biopsy specimens were available in IS
patients. Of the six patients initially without osteitis fibrosa only
one had developed osteitis fibrosa (mild, grade 1.5) at 12
months (no. 3). In the other nine patients osteitis fibrosa
improved or resolved. In patient no. 19 treated with 1 cxOHI)1
this was accompanied by healing of the osteomalacia. Osteoma-
lacia developed for the first time in one patient after 14 months
Fig. 1. Mean (± I so) serum ionized and total calcium levels and serum
phosphate concentrations in patients on CAPD in excess of 6 months.
The shaded area represents the normal range. The number of patients
studied at each point in time are indicated above the so bars. Thirty
patients were on CaCo1 supplements and II on 1 aOHCC. None of
these patients were on ACPB.
of CAPD (no. 5). She had had a total parathyroidectomy after 6
months of CAPD (4 glands, total weight 979 mg) and the bone
stain for aluminum was positive. She had been exposed previ-
ously to aluminum while on hemodialysis; the possibility of
aluminum-induced osteomalacia cannot be excluded. (3) 22 to
24 months of CAPD. Of the five patients studied, two (nos. 2
and 3) showed some mild deterioration in osteitis fibrosa
compared with the previous biopsies at 14 and 12 months,
respectively. In three patients (nos. 4, 5, and 6) there was no
recurrence of the previously improved osteitis fibrosa. Osteo-
malacia persisted at 22 months CAPD in patient no. 5, and the
bone aluminum stain remained positive.
Use (f I aOIICC. Of the 20 patients, only five were treated
with 1 aOHCC (nos. 5, 6, 14, 19, and 20; Table 2).
Aluminum levels. Sequential serum aluminum levels over 0 to
24 months of CAPD treatment are shown in Figure 3. The mean
values at various time periods on CAPD did not differ from the
mean level at the start of CAPD (Table 4). However, these were
significantly higher than the normal controls (mean 2 SD; 7 ±
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Fig. 2. Serial PTH levels in CAPD patients, six of whom with severe OF
previously on hemodialysis requiring parathyroidectomy (0 bottom
figure) 2 to 12 months after starting CAPD.
6 jxg/liter) or the chronic renal failure group not exposed to
aluminum (17 16 gig/liter). However, if the values of these
nine patients with previous aluminum exposure prior to CAPD
are excluded from analysis, there was a steady increase in the
mean values in the remaining patients, although this was not
statistically significant (Table 4).
In most patients without further aluminum exposure in the
form of ACPB, the serum aluminum levels generally steadied at
between 30 and 40 gIIiter, having fallen in those with high
levels (from previous aluminum exposure) and risen in those
with low levels at the start (Fig. 4). Subsequent use of ACPB in
six patients resulted in a marked increase in serum aluminum
levels. Aluminum levels in the PD fluid were 18.25 8.66 zg/
liter and did not vary within or between batches.
Discussion
Over the short period of the study, the majority of patients
showed either definite improvement or no deterioration in the
histological severity of OF. The deterioration in two patients at
2 years was slight. These results are encouraging and suggest
easier management of renal osteodystrophy in patients on
CAPD, with drugs such as 1 aOHCC and avoidance of possible
toxic effects of substances such as aluminum.
One patient who began CAPD had OM which healed com-
pletely at 1 year (patient no. 19, Table 2). Her biopsy specimens
were negative when stained for aluminum. Another patient (no.
Time, months
Fig. 3. Sequential serum aluminum levels over 0 to 24 months on CAPD
patients. Six patients received ACPB after CAPD and their levels are
indicated by ( ) after exposure to aluminum. Nine patients (0) had
aluminum exposure prior to CAPD. Solid circles at time zero relate to
patients not previously exposed to aluminum.
5) who developed OM after parathyroidectomy was on pheny-
tom with 25-(OH)CC levels in the low normal range, but the
cause for OM in her is more likely to be aluminum exposure on
HD prior to starting CAPD. The bone histology substantiates
this because the bone stain for aluminum was positive. The
etiology of her OM in this case is complex, as is the role of
parathyroidectomy in its causation, but it is conceivable that in
the absence of parathormone the toxic effects of aluminum may
become more manifest.
The improvement in histological OF is in contrast with the
radiological deterioration reported by Calderaro et al 121. It is
interesting to speculate why this progression has not been seen
in our patients. The use of PD fluid calcium concentration of
1.75 mmoles/liter in our patients may be crucial in promoting a
positive calcium balance 112] as the lower PD calcium level of
1.50 mmoles/liter may have led to a negative balance [2]. Also in
our series, most patients had low serum ionized calcium levels
Renal osteodystrophy in CAPD patients 19
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Table 4. Mean (± 1 SD) serum aluminum levels in CAPD patients
59.11 49.50
(9)
43.34 28.65
(9)
40.0 20.9
(8)
34.0 19.3
(6)
30.18 29.89
(27)
31.14 20.17
(27)
30.69 14.7
(26)
30.7 13.6
(18)
The numbers in parentheses refer to the number of patients.
0 6 12
when they began CAPD and were treated with oral supplements
of calcium carbonate which also acts as a mild phosphate binder
and may help to counteract the mild acidosis. Phosphate
binding agents have not been used unless the serum phosphate
is persistently greater than 1.8 mmoles/litcr.
Six patients with severe renal osteodystrophy (OF grades, 3
to 4) on HD who were transferred to CAPD showed no
symptomatic biochemical or radiological improvement after 2
to 12 months of CAPD (Fig. 3). They underwent parathyroidec-
tomy. In these patients the severe hyperparathyroidism may be
due to autonomous or "tertiary" stage as four of the six
patients were hypercalcemic without vitamin D or calcium
carbonate supplements.
Our results show that with time serum concentrations of 25-
(OH)CC decline appreciably and that 60% of the patients on
CAPD for longer than 9 months had subnormal levels. The
losses of protein-bound 25-(OH)CC in the PD effluent may
account for the diminishing levels, a mechanism not too dissimi-
lar from that occurring in the nephrotic syndrome [131. It may
be necessary to replace these losses. However, due to vitamin
D resistance, required blood levels may well be higher in renal
failure than in healthy subjects [141 and higher still in CAPD
patients due to losses in the PD effluent. Calderaro et a!
administered 50,000 U of vitamin D weekly to their CAPD
patients and reported normal levels of 25-(OH)CC.
Serum aluminum levels were higher in chronic renal failure
patients not exposed to aluminum compared to normal subjects;
however, levels in CAPD patients were elevated above these
two groups and rose steadily in those starting with normal
serum aluminum levels. This is in contrast to the preliminary
findings of Wolf et al [151 who reported normal values in four
CAPD patients. They were unable to detect aluminum in their
PD fluid. We were able to demonstrate aluminum contamina-
tion of the fluid; it is debatable whether or not this is likely to be
the source of aluminum in patients not taking ACPB. However,
since those patients with initially elevated levels showed a
decline in time to values of 30 to 40 xg/liter, a level also attained
by those not previously exposed to aluminum and starting with
18 normal serum aluminum levels, it is likely that the aluminum
was from the PD fluid, In hemodialysis patients it has been
shown that aluminum transfer is dependent on the free diffus-
ible plasma aluminum concentration, which is usually 20% of
the total plasma value [161. If a similar principle could apply to
peritoneal dialysis, then aluminum would be transferred to the
patient from the PD fluid even when serum levels were higher
than those in the PD fluid, the acceptable aluminum concentra-
tion in the PD fluid would then be one equal to or lower than the
mean value of free diffusible plasma aluminum found in normal
controls. Clearly, more work needs to be done on the kinetics of
aluminum transfer in peritoneal dialysis before a "safe" value
for PD fluid is advocated. However, recently acute aluminum
intoxication in CAPD patients has been reported related to high
PD fluid aluminum levels. These investigators advocate a
"safe" level of about 15 xg/liter; values in excess of these have
been associated with rising serum aluminum levels in their
patients [17]. Their experience is similar to ours: The serum
aluminum rose further in patients exposed to ACPB.
Several crucial questions arise. Firstly, is the steady state
serum aluminum level of about 30 xg/liter of any significance
over a period of years? At present there is no evidence that this
level maintained for a number of years leads to aluminum
toxicity. Certainly over the 2 years none of the CAPD patients
developed OM of the type previously found in our hemodialysis
population. What may be more important to establish is wheth-
er or not the aluminum burden increases with time and what
aluminum load is reflected by a serum aluminum level of 30 to
40 pg/liter. This currently is difficult since the serum level
0
S to 8
10 to 13
15 to 19
Time Aluminum exposure Group without aluminum
months Total group prior to CAPD exposure
21.8 12.36
(18)
26.78 9.1
(18)
27.52 10.5
(18)
28.85 7.46
(12)
Time, months
Fig. 4. Serial serum aluminum levels in six patients, three of whom with
elevated levels and three with normal levels at the start of CAPD.
Symbols: C 0, previous exposure to aluminum; S—•, no expo-
sure to aluminum.
Renal osteodystrophy in CAPD patients 21
reflects only recent aluminum exposure; thus, even at these
levels there is a small, long-term potential risk of aluminum
toxicity especially if ACPB, which led in this study to a rise in
aluminum levels, are necessary to control serum phosphate
levels. It would then be important to obtain dialysis fluid with as
low an aluminum content as is possible and look for a nonalu-
minum containing phosphate binding agent.
Desferrioxamine is normally a good iron chelator and has
been used for this purpose in several conditions of iron loading
including hemodialysis [181. It is also able to chelate aluminum
in tissues [11]. On CAPD the aluminum losses are small.
Nonetheless, patients showing toxic effects attributable to
aluminum may benefit from treatment by CAPD, which does
reduce high serum aluminum levels, and, in addition, leads to
easier control of serum phosphate.
To minimize the aluminum problem and to manage the low
levels of 25-(OH)CC, our current practice is to administer
calcium carbonate supplements to normalize serum ionized
calcium concentrations. 1 aOHCC is prescribed if either 25-
(OH)CC levels are low and/or if there is histological or clinical
evidence of OF or OM. The serum phosphate concentration is
maintained below 1.8 mmoles/liter (normal range, 0.8 to 1.5) by
calcium carbonate and dietary phosphate restriction. If this is
unsuccessful, then phosphate binding agents are introduced and
serum aluminum concentrations are monitored.
There is the risk that, with time, the persistently positive
calcium balance achieved by using 1.75 mmoles/liter calcium
concentration in the PD fluid [121, may lead to metastatic
calcification, especially if this is combined with 1 aOHCC,
calcium supplements, and possible high serum phosphate lev-
els. The dorsalis pedis calcification in the long-term CAPD
patients in this study may be a reflection of this and demands
careful monitoring of serum ionized calcium and phosphate
concentrations. There is a need for constant review of the PD
fluid calcium concentration as a lower concentration may be
necessary in long-term patients once calcium depletion is
corrected.
In conclusion, CAPD appears to achieve good control of
renal osteodystrophy. However, 25-(OH)CC levels are low and
patients may need cautious amounts of vitamin D replacement
therapy. Serum aluminum levels are elevated in those patients
not exposed to ACPB and this may be related to the PD fluid
aluminum content. The levels rise further when ACPB are
introduced, though this has not, to date, resulted in toxicity.
Nonetheless, it would seem advisable to minimize aluminum
contamination of PD fluid.
Summary. Eleven of the 20 paired bone biopsy specimens
showed significant improvement is osteitis fibrosa (OF) 4 to 14
months after CAPD (five on 1 cOHCC), and in five patients at 2
years there was no significant deterioration. Six patients with-
out OF at the beginning remained unchanged at 12 months while
one patient developed osteomalacia (OM) after parathyroidec-
tomy. These patients, managed on calcium carbonate supple-
ments and in most cases no aluminum-containing phosphate
binders (ACPB), maintained normal serum ionized and total
calcium levels while mean serum phosphate levels ranged
between 1.5 and 1.8 mmoles/liter on a dialysate calcium of 1.75
mmoles/liter. There was a decline in the parathormone level in
all but ten patients, six of whom with previous severe OF on
hemodialysis required parathyroidectomy. 25-(OH)CC levels
declined to subnormal levels related to losses in the PD fluid in
the majority of patients. Mean serum aluminum levels were
higher than normal health controls; these may have been related
to aluminum in the PD fluid. Levels rose further when ACPB
was introduced. One patient with aluminum toxicity from prior
exposure was treated with desferrioxamine given parenterally
with the removal of the chelated aluminum in the PD fluid.
CAPD appeared to achieve good control of renal osteodys-
trophy, but 25-(OH)CC levels were low and cautious amounts
of vitamin D replacement therapy may be necessary. Serum
aluminum levels were elevated and these may be related to the
PD fluid aluminum content.
Reprint requests to Dr. R. Gokal, Renal Unit, Manchester Royal
Infirmary, Oxford Road, Manchester, M13 9WL, United Kingdom
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